A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
NCT05933070
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class
Stopped
Slow/low Enrollment
Conditions
Cancer
MDS-EB
Myelodysplastic Syndromes
Acute Myeloid Leukemia
AML
Interventions
BIOLOGICAL:
INKmune
Sponsor
Inmune Bio, Inc.